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 ABSTRACT 
 A number of health and lifestyle factors are thought to contribute to cognitive decline associated with age 
but cannot be easily modifi ed by the individual patient. We identifi ed 12 individually modifi able interventions 
that can be implemented during midlife or later with the potential to ameliorate cognitive aging. For ten of 
these, we used PubMed databases for a systematic review of long-duration (at least 6 months), randomized, 
controlled trials in midlife and older adults without dementia or mild cognitive impairment with objective 
measures of neuropsychological performance. Using network meta-analysis, we performed a quantitative 
synthesis for global cognition (primary outcome) and episodic memory (secondary outcome). Of 1038 
publications identifi ed by our search strategy, 24 eligible trials were included in the network meta-analysis. 
Results suggested that the Mediterranean diet supplemented by olive oil and tai chi exercise may improve 
global cognition, and the Mediterranean diet plus olive oil and soy isofl avone supplements may improve 
memory. Effect sizes were no more than small (standardized mean differences 0.11 – 0.22). Cognitive training 
may have cognitive benefi t as well. Most individually modifi able risk factors have not yet been adequately 
studied. We conclude that some interventions that can be self-initiated by healthy midlife and older adults 
may ameliorate cognitive aging. 
 INTRODUCTION 
 Each of us is responsible for our own health, and many aspects 
of healthy aging are under our direct control. With good rea-
son, we are admonished to stop smoking, exercise regularly, 
and use sun screen. Concerns with memory and cognitive 
abilities are increasingly common in midlife and older adult-
hood. For cognitive aging, advice abounds, but it is less cer-
tain what the individual can do to maintain or improve mental 
abilities. The purpose of this systematic review is to evaluate 
evidence on (a) common, modifi able risk factors for (b) cogni-
tive aging that are (c) largely under the individual ’ s personal 
control and (d) can be implemented in midlife or later. 
 We do not focus directly on factors linked to the risk of 
dementia. Interventions that might prevent cognitive aging are 
not necessarily identical to those that might reduce risk of 
Alzheimer ’ s disease or another dementia. There are, however, 
shared risk factors. Moreover, an intervention that amelio-
rates cognitive aging would be expected at the same time to 
reduce the likelihood of dementia by augmenting cognitive 
reserve, improving brain health, or both 1 . Cognitive reserve is 
enhanced by increasing the capacity, effi ciency or redundancy 
of brain areas and neural pathways used when a cognitive 
task is performed 2 . Educational attainment, for example, is 
associated with reduced risk of dementia 3 . Brain health might 
be boosted by improved microcirculation, reduced oxidative 
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stress, enhanced glymphatic clearance of toxic metabolites, 
and other mechanisms. 
 Cognitive aging, mild cognitive impairment, and 
dementia 
 Cognitive abilities change over the life span, and performances 
on many  – but not all  – cognitive tasks show decline during 
midlife and older adulthood. The most severe form of cogni-
tive deterioration is dementia, also referred to as major neu-
rocognitive impairment. Dementia is caused by specifi c brain 
pathologies, such as the neuritic plaques and neurofi brillary 
tangles of Alzheimer ’ s disease or cerebral infarction charac-
teristic of dementia due to cerebral vascular disease. In most 
instances, dementia is preceded by a stage of milder decline 
(mild cognitive impairment, or MCI) 4 , where the overall path-
ological burden is less severe than in dementia. 
 Cognitive aging represents decline in the absence of specifi c 
dementia pathologies. The underlying physiological processes 
are poorly characterized but are not thought to eventuate in 
dementia, absent co-existing dementia pathologies. Cognitive 
aging and MCI, however, are not always easily distinguished, 
and by the tenth decade of life some degree of dementia 
pathology is near-universal. 
 Midlife and beyond 
 Our analyses focus on interventions that can be implemented 
in midlife or later, a time when cognitive concerns are height-
ened, and presumably before there is evidence of pathological 
decline indicative of MCI or dementia. We include men as well 
as women because  – apart from hormonal exposures  – many 
modifi able risk factors pertain to both sexes, and many 
clinical trials still do not report separate outcomes for women 
and men. 
 For women, midlife is conceptualized to begin with the 
menopausal transition, as the reproductive phase of a woman ’ s 
life draws to a close. Natural menopause, defi ned retrospec-
tively after 12 months of amenorrhea 5 , occurs at a median age 
of 51 years, and menstrual cycle irregularity characteristic of 
the menopausal transition begins on average about 4 years 
before. For men, where reductions in gonadal testosterone 
occur gradually throughout adult life 6 , midlife might some-
what arbitrarily be said to begin at age 50. For women and 
men, midlife continues up until age 65 years, the traditional 
threshold for older adulthood. 
 Individually modifi able risk factors 
 In their exhaustive report on preventing Alzheimer ’ s disease, 
MCI, and cognitive decline, Williams and colleagues 7 tackled 
a broad range of exposures and interventions. A number of 
factors identifi ed in their analyses are of public health import 
yet do not offer meaningful opportunities for at-risk individu-
als at midlife or older. 
 This dilemma is especially true for medical conditions. 
Important disorders considered by Williams and colleagues, 
such as diabetes mellitus, hypertension, hyperlipidemia, and 
depression, require treatment regardless of how the illness 
might  – or might not  – impact cognitive aging. For most 
prescription drugs, options for individual patients are simi-
larly limited. Side-effect profi les and personal preference 
can help guide selection, but the decision whether or not to 
treat is usually not open to debate. Cigarette smoking can be 
viewed analogously. This lifestyle factor is strongly associated 
with cardiovascular disease, stroke, lung cancer, and overall 
mortality. Public health exhortations to stop smoking will be 
largely unaffected by cognitive considerations. The individual 
smoker already knows she should stop. 
 Williams and colleagues 7 also discuss social factors 
associated with cognitive health. Some, however, cannot 
be addressed by middle-age and older adults. One ’ s early 
childhood environment is not modifi able in adulthood. Most 
critical decisions on education or occupation are made well 
before midlife. Marital status can change at any age but would 
seem diffi cult to modify on the basis of cognitive concerns. 
 The midlife or older adult, however, has direct control over 
many lifestyle practices and nutritional factors. In addition, 
menopausal hormone therapy (MHT) is a notable exception 
to the non-discretionary nature of prescription drugs. For its 
most common indication  – the treatment of moderate to severe 
vasomotor symptoms  – its use  is often viewed as discretion-
ary. There are alternative forms of pharmacologic and non-
pharmacologic therapies 8 , which are often recommended in 
preference to MHT. A woman ’ s informed decision is increas-
ingly the critical factor in whether MHT is prescribed. 
 Risk factor selection 
 Based on these considerations, we identifi ed 12 individually 
modifi able factors. For ten of these, we undertook a system-
atic review and quantitative synthesis. For two others, we 
relied on recently published meta-analyses (Table 1). Each 
selected intervention can be implemented during or after 
midlife. For each, the key question was,  ‘ What are the cogni-
tive effects of the intervention? ‘ . Because randomized, 
controlled trials provide the strongest evidence for causality, 
our systematic reviews and synthesis were based on clinical 
trial fi ndings. We used other evidence, including fi ndings from 
longitudinal observation and prior systematic reviews, to 
frame the issues and discuss our results. 
 METHODS 
 Approach 
 Our approach is given below and summarized in Table 2. 
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 Evidence 
 Systematic searches were based on randomized, controlled tri-
als involving a single active intervention and a placebo or 
presumably inactive comparator. Where blinding was feasible  – 
for example, when the intervention was a prescription drug 
or nutritional supplement  – we sought confi rmation that par-
ticipants and evaluators were blinded. Where participant 
blinding was not feasible  – for example, tai chi exercise or the 
Mediterranean diet  – we required blinded outcome assess-
ment. To reduce publication bias 9 , we required evaluable out-
comes from at least 50 trial participants. Because we were 
interested in long-term, sustained cognitive benefi t, we required 
at least 6 months between intervention initiation and outcome 
assessment. 
 Participant characteristics 
 Participants of eligible trials were midlife or older, recruited 
from a generally healthy population, and without MCI, 
dementia, or a specifi c medical disorder. We allowed at-risk 
populations (e.g. elevated serum concentrations of homo-
cysteine) without end-organ disease (e.g. stroke). For samples 
with younger adults, the mean age had to be at least 50 years. 
We considered studies of women, men, and both sexes com-
bined. Most trials included men and women; very few pro-
vided sex-specifi c cognitive outcome data that would allow an 
examination of possible interactions by sex. For hormonal 
interventions, we were interested in the possibility that a 
woman ’ s age or temporal proximity to menopause might 
modify effects of the intervention. Few trials provided these 
data, however, and we were unable to address issues of timing 
in a systematic manner. 
 Search strategy and data abstraction 
 We searched PubMed databases through May 2015 to identify 
eligible trials in any language, as long as an English-language 
abstract was available. To identify other clinical trials, we 
examined reference lists from acquired trials and recent 
meta-analyses. Medical Subject Heading (MeSH) search terms 
and keywords for searches are in Supplemental Table S1, 
to be found online at http://informahealthcare.com/doi/abs/
10.3109/13697137.2015.1078106. 
 Using prespecifi ed inclusion and exclusion criteria, 
titles and abstracts were examined for potential relevance. 
Neuropsychological tests were categorized as tests of memory 
or general intelligence or as screening cognitive tests (Table 2). 
Memory tests were conceptualized as representing cognitive 
functions mediated by the hippocampus and adjacent medial 
temporal lobe areas, and general intelligence tests as repre-
senting functions mediated by neocortical association cortex. 
 Table 1 Personally modifi able, midlife and older life interventions 
with the potential to ameliorate cognitive aging 
 Factor  Classifi cation 
B-vitamin supplements  *  Nutritional supplement
Dehydroepiandrosterone Nutritional supplement or 
prescription drug  †  
 Ginkgo biloba extract Nutritional supplement
Mediterranean diet Dietary factors
Menopausal hormone therapy  * *  Prescription drug
Mindfulness Lifestyle
Omega-3 polyunsaturated fatty 
acids
Dietary factor or nutritional 
supplement
Social engagement Lifestyle
Soy isofl avones  † †  Dietary factor or nutritional 
supplement
Vitamin D supplements  ‡  Nutritional supplement
Cognitive activity and cognitive 
training
Lifestyle
Physical activity (aerobic exercise) Lifestyle
  *  , Folic acid, vitamin B12, and/or vitamin B6, not part of a broadly 
construed nutritional or multivitamin supplement;   †  , dietary 
supplement in the US, controlled drug in most other countries;   ‡  , not 
part of a broadly construed nutritional or multivitamin supplement; 
  * *  , oral, transdermal or parenteral, excludes topical (vaginal) 
formulations;   † †  , soy food products or soy isofl avone supplements 
 Table 2 Inclusion and exclusion criteria for systematic review 
 Category  Criteria 
Study populations Midlife and older adult women or men; 
drawn from a generally healthy general 
population; without dementia or mild 
cognitive impairment
Sample size At least 50 participants with evaluable 
outcomes
Interventions See text and Table 1
Duration 6 months or longer
Evaluable outcomes Change in cognition, based on objective, 
quantitative neuropsychological tests  *  
Primary cognitive 
outcome
Global cognition: based on all available 
neuropsychological tests, including tests 
of episodic memory, general intelligence, 
and screening cognition
Secondary cognitive 
outcome
Episodic memory: based on tests of verbal 
or non-verbal learning and recall 
(immediate and delayed recall of 
supraspan information, including 
recognition and incidental recall)  †  
 * , Excluded tests of  ‘ premorbid ’ intelligence, such as tests of 
vocabulary or the pronunciation of orthographically irregular words, 
and tasks primarily conceptualized as non-cognitive, such as fi nger-
tapping;   †  , examples are the Benton Visual Retention Test, California 
Verbal Learning Test, Hopkins Verbal Learning Test, and paired-
associates learning. General intelligence encompassed tests of working 
memory, executive functioning, semantic memory, perceptual speed, 
and visuoconstruction. Examples of screening cognitive tests (screening 
cognition) are the Mini-Mental State examination and the Telephone 
Interview of Cognitive Status 
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Screening cognitive tests were relative short instruments that 
incorporated both memory and general intelligence items. 
Data from published reports were summarized in evidence 
tables by one reviewer and verifi ed by a second. Other studies 
were reviewed qualitatively. 
 Data synthesis 
 We focused on continuous measures of cognitive function. 
Categorical ratings based on cut scores are often arbitrary, 
of uncertain clinical relevance, and fail to take advantage of 
the full range of information contained within a continuous 
measure. Although categorical ratings such as transition to 
MCI are clinically meaningful, they typically involve assess-
ment of both cognitive and non-cognitive processes. The 
transition also implicates specifi c pathological processes, 
such as those linked to Alzheimer ’ s disease 10 . We were inter-
ested in cognitive decline independent of non-cognitive 
change and without implicit links to inferred pathologies. 
Our primary endpoint was global cognition derived from all 
neuropsychological test scores. Our secondary outcome was 
memory based both on verbally mediated tests of episodic 
memory and on tests less amenable to verbal encoding and 
retrieval strategies. We recognize that some interventions 
might have relatively isolated, domain-specifi c effects, or 
that some effects might be positive within one cognitive 
domain and neutral or negative in another. However, we 
were particularly concerned with the net benefi t or harm of 
an intervention on overall cognitive functioning and, second-
arily, on overall memory skills. 
 Statistical methods 
 We undertook a network meta-analysis to examine effects of 
individually modifi able risk factors on cognitive outcomes. 
This approach combines information from multiple trials that 
compare two or more interventions for a given disorder and 
provides indirect comparisons between interventions in differ-
ent studies 11, 12 . Neuropsychological tests were identifi ed as 
providing memory (secondary outcome), general intelligence 
or screening cognitive test outcomes (see Table 2 for exam-
ples). Our primary outcome (global cognition) used results of 
all tests. Within each study, effect size variances were adjusted 
to account for multiple comparisons and endpoints. For each 
activecontrol intervention, we calculated standardized mean 
differences (effect sizes) and adjusted standardized errors. 
Effect sizes of at least 0.2 but less than 0.5 are usually described 
as  ‘ small ’ . We report nominally signifi cant (two-tailed  p    0.05) 
standardized mean differences    0.1 as having potential clini-
cal relevance, and describe these differences as very small (0.1 
to    0.2) or small (0.2 to    0.5). Our initial approach used 
fi xed-effect models, under the assumption that interventions 
would have comparable effects on cognitive outcomes in other 
populations of healthy midlife and older populations. We used 
a random-effects model in sensitivity analyses 13 . Statistical 
analyses were performed using R statistical packages (release 
3.2.0) and the meta-library Netmeta 14 . 
 RESULTS 
 Of the 1038 publications identifi ed by our search strategy (see 
Supplementary Table S1, to be found online at http://informa
healthcare.com/doi/abs/10.3109/13697137.2015.1078106), 
24 eligible clinical trials were included in the network 
meta-analysis, with 490 treatment arms for three groups of 
cognitive endpoints (memory, general intelligence, screening 
cognition). 
 A funnel plot of the treatment effect versus standardized 
error of the treatment effect showed a balanced distribution, as 
evidence for absence of publication bias. Results of fi xed-effect 
models for memory, general intelligence and screening cogni-
tion did not indicate heterogeneity among studies (Cochran 
Q:  p    0.21 – 0.91,  I 2    0.0 – 8.4%,  τ 2    0.001 – 0.0012); results 
were similar for global cognition (Cochran Q:  p    0.31, 
 I 2    4%,  τ 2    0.0004). Similar fi ndings for memory, general 
intelligence and screening cognition justifi ed a general pooling 
of the network (Kendall rank correlation coeffi cient    0.91; 
good internal consistency (Cronbach  α    0.89); 73% of vari-
ance explained by the fi rst principal component in a principal 
components analysis). Results from random effects models 
were virtually identical to those of fi xed effect models (see 
Supplementary Tables S2 and S3, to be found online at http://
informahealthcare.com/doi/abs/10.3109/13697137.2015.
1078106). Some fi ndings for the two Mediterranean diets 
and two mindfulness interventions (tai chi and yoga) differed 
signifi cantly from each other and are described separately. 
 Most interventions had no signifi cant effect on any cogni-
tive outcome (results for global cognition and memory are 
shown in Figure 1). Two had signifi cant positive effects on 
global cognition that were small (Mediterranean diet   olive 
oil: standardized mean difference 0.22, 95% CI 0.16 – 0.27) or 
very small (tai chi exercise: standardized mean difference 0.18, 
95% CI 0.06 – 0.29). Two interventions had small (Mediter-
ranean diet   olive oil: standardized mean difference 0.22, 
95% CI 0.12 – 0.32) or very small (soy isofl avone supplements: 
standardized mean difference 0.11, 95% CI 0.04 – 0.17) posi-
tive effects on memory. Nominally signifi cant differences for 
global cognition below our threshold for potential clinical 
relevance were noted for MHT (negative: standardized mean 
difference -0.03, 95% CI -0.05 to -0.01), soy isofl avones (pos-
itive: standardized mean difference 0.04, 95% CI 0.002 – 0.08) 
and the Mediterranean diet   nuts (positive: standardized 
mean difference 0.08, 95% CI 0.03 – 014). 
 DISCUSSION 
 B-vitamins 
 There is an intriguing relation between homocysteine, B-vitamins, 
and cognitive impairment. Homocysteine is a sulfur-containing 
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amino acid derived from methionine. Circulating levels 
increase with age, and higher homocysteine levels are associ-
ated with several important disorders, including coronary 
heart disease and Alzheimer ’ s disease. Vitamin B12 (cobalamin), 
folic acid (vitamin B9), and vitamin B6 (pyridoxine) are co-
factors in the conversion of methionine to homocysteine. 
Lower blood levels of folic acid and vitamin B12 are associ-
ated with Alzheimer ’ s disease 15 , and B-vitamin supplements 
reduce homocysteine levels 16 . 
 Despite some encouraging fi ndings  – for example, less 
brain atrophy in MCI patients treated with folate and vitamin 
B12 17  – cognitive endpoints in randomized trials have often 
been null, both for dementia patients and for adults with 
normal cognition 18 . 
 Four clinical trials met our search criteria, conducted 
over periods of 2 or 3 years 19 – 22 . Each was limited to older 
adults; participants in three trials were preselected on the 
basis of elevated plasma homocysteine. The active interven-
tions were folate (400 – 2000  μ g; four trials) plus vitamin 
B12 (400 or 500  μ g; three trials) and vitamin B6 (10 or 
25 mg; two trials). The B-vitamin interventions effectively 
lowered homocysteine levels. One trial reported improved 
memory and other cognitive skills with folate supplements 19 , 
and three reported no cognitive effect of B-vitamin interven-
tion 20 – 22 . Our meta-analysis indicated no benefi t for global 
cognition or memory. 
 Dehydroepiandrosterone 
 Dehydroepiandrosterone (DHEA) is a weakly androgenic 
steroid secreted by the adrenal cortex. Small quantities are 
also produced within the brain. It is an intermediary in the 
biosynthesis of androgens and estrogens. DHEA or its sulfate 
ester has been hyped as a superhormone and as an anti-aging 
hormone. It is the most abundant circulating steroid, and 
levels in women and men decline dramatically with age. Inter-
est in DHEA is particularly keen in the US, where it is classi-
fi ed as a dietary supplement and can be purchased over the 
counter. In most countries, it is available only by prescription, 
including the UK where it is regulated as a Class C drug. 
 A Cochrane review concluded that evidence did not sup-
port a benefi cial effect of DHEA supplementation on cognitive 
function of middle-age or older adults without dementia 23 . 
One clinical trial met our search criteria. In this 12-month 
US study, 225 midlife and older men and women were 
randomized to DHEA 50 mg daily or placebo 24 . Consistent 
with the interpretation of study authors, we identifi ed no 
cognitive benefi t. 
 Ginkgo biloba 
 Ginkgo biloba is extracted from leaves of the  Ginkgo biloba 
tree, described as a living fossil unrelated to other extant tree 
species. The extract is marketed as a dietary supplement, often 
with claims that it boosts memory. It has been tested in 
patients with MCI and dementia, as well as cognitive aging. 
Smaller trials found Ginkgo biloba extract promising in 
stabilizing or slowing decline in cognitively impaired patients 
with neuropsychiatric symptoms 25 . However, very large clini-
cal trials in the US and France found no evidence that Ginkgo 
biloba reduced the incidence of dementia over a 5- or 6-year 
period 26,27 . 
 Fewer studies have assessed the effects of Ginkgo biloba on 
cognitive aging. Cognitive decline was assessed as a secondary 
outcome in the Ginkgo Evaluation of Memory trial 27 . The 
study enrolled over 3000 community-dwelling adults aged 
Intervention
B-vitamins
DHEA
Med. Diet + nuts
Med. Diet + oliveoil
MHT
Omega-3
Social engagement
Soyisoflavones
Tai chi
Vitamin D
Yoga
0.02 (0.00, 0.05)
0.06 (–0.09, 0.22)
0.08 (0.03, 0.14)
0.22 (0.16, 0.27)
–0.03 (–0.05,–0.01)
–0.01 (–0.04, 0.01)
0.12 (–0.01, 0.25)
0.04 (0.00, 0.08)
0.18 (0.06, 0.29)
0.00 (–0.04, 0.04)
0.02 (–0.12, 0.16)
–
0
.2
–
0
.1 0
0
.1
0
.2
–
0
.3
0
.3
Global cognition
0.04 (0.00, 0.08)
0.12 (–0.15, 0.39)
0.07 (–0.03, 0.17)
0.22 (0.12, 0.32)
–0.01 (–0.04, 0.03)
0.02 (–0.04, 0.07)
0.20 (–0.08, 0.47)
0.11 (0.04, 0.17)
0.24 (–0.03, 0.51)
–0.01 (–0.08, 0.06)
0.06 (–0.38, 0.50)
–
0
.2
–
0
.1 0
0
.1
0
.2
–
0
.3
0
.3
0
.4
Episodic memory
 
 Figure 1 Results of the network meta-analysis. Fixed-effects model. Weighted standardized mean differences and 95% confi dence intervals 
by intervention for primary (global cognition) and secondary (episodic memory) outcomes. DHEA, dehydroepiandrosterone; Med. Diet, 
Mediterranean diet; MHT, menopausal hormone therapy; Omega-3, omega-3 fatty acids 
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72 years and older. The study cohort included patients with 
MCI as well as cognitively normal participants. When com-
pared to placebo, Ginkgo biloba extract over 6 years did not 
reduce declines in memory or other cognitive functions 28 . One 
clinical trial would have otherwise met our eligibility criteria, 
except that data were not in a form that we could extract for 
quantitative analysis. This 42-month US study of 118 cog-
nitively normal participants over 84 years of age found no 
signifi cant difference in memory decline between participants 
allocated to Ginkgo biloba or placebo 29 . 
 Mediterranean diet 
 The Mediterranean diet holds promise as a palatable approach 
to the remediation of cognitive aging. There is no one specifi c 
Mediterranean diet. Rather, the diet refl ects traditional 
patterns of food consumption in Greece, southern Italy, Spain, 
and Portugal. Characteristics include relatively large propor-
tions of fi sh and relatively low proportions of meat; unsatu-
rated fatty acids such as those found in olive oil; legumes, 
fruits, vegetables, and unprocessed cereal grains; moderate 
amounts of cheese, yogurt, and other dairy products; and 
moderate quantities of wine. Observational research suggests 
that higher adherence to a Mediterranean diet is associated 
with lower risks of MCI and Alzheimer ’ s disease 30 . In the 
Nurses ’ Health Study, long-term adherence to a Mediterra-
nean diet was associated with moderately better cognition but 
was unrelated to cognitive change 31 . 
 One clinical trial met our search criteria. This was a multi-
site study of over 1000 Spanish participants aged 55 – 80 years 
with diabetes or other cardiovascular risk factors. Participants 
were randomized to one of two versions of the Mediterranean 
diet (supplemented with extra virgin olive oil (Mediterranean 
diet   olive oil) or mixed nuts (Mediterranean diet   nuts)) 
or to a low-fat diet control diet. At the Navarra study site, 
cognitive function was screened 6.5 years after randomiza-
tion 32 , with detailed testing on a subset of participants 33 . At 
the Barcelona site, neuropsychological tests were administered 
at baseline and about 4 years later 34 . Substantial numbers of 
participants were lost to follow-up or excluded. Compared 
to the low-fat diet, both Mediterranean diets were reported 
to improve aspects of cognitive function. Our meta-analysis 
suggested better global cognition and memory with the 
Mediterranean diet   olive oil. 
 Menopausal hormone therapy 
 After menopause, the depletion of ovarian follicles leads to 
permanent reductions in circulating levels of estrogens and 
progesterone, although small amounts continue to be made 
within the brain. These hormonal changes can affect neural 
processes concerned with cognition and pathological pro-
cesses linked to Alzheimer ’ s disease. 
 Cognitive complaints are common during midlife, and 
the menopausal transition may represent a time of cognitive 
vulnerability 35 . It is controversial whether MHT, a systemic 
estrogen with or without a progestational agent, benefi ts or 
harms cognitive abilities 36 . A related controversy concerns 
MHT effects on Alzheimer ’ s disease. Clinical trial evidence 
from the Women ’ s Health Initiative (WHI) indicates that 
MHT increases dementia risk in women after age 65 years and 
older, whereas observational data link MHT use at younger 
ages to reduced Alzheimer risk 37 – 39 . 
 We identifi ed six eligible trials for review and quantita-
tive synthesis. All involved women aged 60 years and older. 
The MHT formulation in most trials was conjugated estro-
gens 0.625 mg/day with or without medroxyprogesterone 
acetate 40 – 45 ; other formulations were low-dose transdermal 
estradiol 0.014 mg/day 46 and oral estradiol 1 mg/day and 
norethindrone 47 . Most comparisons with placebo were nil. 
In single studies, differences favored placebo on a screening 
cognitive test 40 and a test of verbal memory 42 and favored 
MHT on a non-verbal memory test 42 . Our meta-analysis 
of the six trials suggested no clinically meaningful effect of 
MHT compared to placebo on global cognition or memory, 
with nominal effects on global cognition (standardized mean 
difference -0.03) that favored placebo. 
 Few clinical trials of MHT have included younger 
postmenopausal women, and none met our inclusion criteria. 
Small clinical trials in surgically menopausal women suggest 
short-term cognitive benefi t of MHT when started at the time 
of oophorectomy 36 . A large 4-month trial of recently meno-
pausal women with cognitive complaints found no cognitive 
benefi t of conjugated estrogens 0.625 mg/day plus medroxy-
progesterone acetate in women aged 45 – 55 years 48 . A three-
arm trial published too late to be included in our systematic 
review provides results from 693 younger postmenopausal 
women, mean age 53 years. Women were allocated to con-
jugated estrogens 0.45 mg/day and oral micronized proges-
terone, to transdermal estradiol 0.05 mg/day and micronized 
progesterone, or to placebo 49 . Cognitive outcomes at nearly 
3 years did not differ signifi cantly among treatment groups. 
The timing hypothesis is examined more directly in a large, 
recently completed randomized trial that includes both 
younger and older postmenopausal women randomized to 
oral estradiol with or without micronized progesterone, vagi-
nal gel or placebo 50 ; these fi ndings are not yet published. 
 Mindfulness 
 Mindfulness is a mental state characterized by the focus of 
attention on the present moment. The attentional spotlight 
often includes bodily sensations  – for example, propriocep-
tive sensations related to breathing or posture  – as well as 
stimuli arising from the external environment. Mindfulness 
is intentional, non-analytical, and non-judgmental. It is an 
important component of meditation and mind-body practices 
such as yoga, tai chi, and qi gong. Mindfulness interventions 
have been most studied in relation to psychological stress, 
anxiety, and depression. Some investigators have examined 
cognitive outcomes as well. A recent meta-analysis of tai chi 
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trials concluded that tai chi improves executive cognitive 
functions 51 . 
 Our systematic search focused on meditation, yoga, tai chi, 
and qi gong. We identifi ed three eligible trials. A 6-month 
trial of Hatha yoga found no cognitive benefi t compared to 
wait-list controls 52 . In contrast, tai chi exercises performed for 
6 months (US) 53 or 40 weeks (Shanghai, China) 54 improved 
several neuropsychological measures. The Shanghai investi-
gators reported signifi cant increases in brain volume in the 
tai chi group compared to the no-intervention control 54 . Our 
meta-analysis indicates that tai chi exercise improves global 
cognition. 
 Omega-3 polyunsaturated fatty acids 
 Low rates of cardiovascular disease among the Inuit of 
Greenland are associated with high dietary intakes of fi sh. 
This observation led to studies on health effects of omega-3 
fatty acids. These are n-3 long-chain polyunsaturated fatty 
acids, where n-3 refers to the location of the last carbon – 
carbon double bond, three carbons from the end of the fatty 
acid backbone. Two, docosahexaenoic acid (DHA) and 
eicosapentaenoic acid (EPA), are obtained primarily from 
certain fatty fi sh and their oils. The brain contains large 
amounts of DHA, an important component of nerve cell 
membranes. A Cochrane review found no clear role for 
omega-3 fatty acids in modifying dementia risk and no clear 
benefi t of omega-3 supplementation on cognitive abilities in 
healthy older adults 55 . 
 Three clinical trials met our search criteria. Active interven-
tions were capsule supplements of EPA-DHA or ethyl-esters 
of n-3 polyunsaturated fatty acids 56 – 58 . The largest  – a mul-
tinational trial targeting midlife and older adults with mild 
diabetes, abnormal fasting glucose levels, or impaired glu-
cose tolerance  – followed several thousand participants for a 
median of 6.2 years 56 . None of the studies reported cognitive 
benefi t compared to placebo, and our meta-analysis confi rmed 
the absence of cognitive effect. 
 Social engagement 
 Social engagement is postulated to reduce risk for cognitive 
aging and dementia. Social engagement has been variously 
assessed  – usually by self-report  – from marital status, number 
of people within a household, size of social network, or par-
ticipation in social activities. Observational fi ndings on social 
engagement and cognition are inconsistent 7 . 
 Clinical trials that assess social engagement typically use a 
design that introduces other activities at the same time. For 
example, a pilot trial of volunteer service in elementary school 
settings provided participants with not only new social net-
works but also with new cognitive challenges and enhanced 
physical activity 59 . This multimodal approach is quite reason-
able but makes it diffi cult to discern the contribution of social 
engagement  per se . 
 One trial met our search criteria, the 40-week clinical 
trial conducted in Shanghai, China, referred to above, which 
included a social interaction arm and a no-intervention con-
trol 54 . Social interaction occurred within an  ‘ extremely lively ’ 
discussion group that met for 1 hour, three times weekly under 
the direction of a group leader. We did not fi nd a signifi cant 
effect of social engagement on cognitive outcomes. 
 Soy isofl avones 
 Isofl avones are plant-derived diphenolic compounds structur-
ally similar to estrogens. They are sometimes classifi ed as 
selective estrogen receptor modulators, since biological effects 
can be estrogenic or antiestrogenic in the brain and in other 
tissues. Soy, the major dietary source of isofl avones, is a staple 
of traditional diets in some Asian countries. Soy isofl avones 
have been investigated in relation to breast cancer, prostate 
cancer, cardiovascular disease, menopausal vasomotor symp-
toms, osteoporosis, and other health outcomes. Observational 
studies in countries where soy dietary consumption is rela-
tively low generally report no associations with cognition. 
Some investigations in populations with higher levels of 
consumption report adverse associations 60,61 . Cognitive effects 
of different soy products might differ 61 . 
 Four clinical trials, all involving healthy postmenopausal 
women, met our search criteria: two from the US 62,63 , one 
from Hong Kong 64 , and one from the Netherlands 65 . Sample 
sizes ranged from 53 to 313, with follow-up times of 6 to 
30 months. The active interventions were 80 – 110 mg daily 
of soy-derived isofl avone supplements. Where specifi ed, 
supplements contained genistein, daidzein, and glycitein in 
the approximate ratio found in soy. 
 Most comparisons between treatment groups did not differ. 
One trial reported better category fl uency in the isofl avone 
group 62 and one trial reported worse performance on a work-
ing memory task and better performance on a visual memory 
task 63 . The largest, longest trial found no treatment effect on 
a composite neuropsychological measure of global cognition 
but better performance in the isofl avone group on a composite 
measure of visual memory 63 . In this trial, treatment group 
comparisons on composite neuropsychological measures did 
not differ between women less than age 60 years compared to 
women aged 60 and above. In secondary analyses, there was 
an inverse association between the level of endogenous expo-
sure (measured by urinary isofl avonoids) and performance 
on neuropsychological tests of general intelligence (but not 
memory) 66 . Our meta-analysis indicated that soy isofl avone 
supplements improve memory but have no effect on global 
cognition. 
 Vitamin D 
 Vitamin D refers to several related fat-soluble steroid deriva-
tives, including vitamin D3 (1,25-dihydroxycholecalciferol, or 
1,25-dihydroxyvitamin D) and vitamin D2 (ergocalciferol). 
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Few foods contain vitamin D, and vitamin D defi ciency is 
common in many areas of the world 67 . Dietary vitamin D3 is 
obtained from fi sh oils and fortifi ed dairy products. The major 
natural source comes from conversion of 7-hydroxycholes-
terol to cholecalciferol in the skin in the presence of sunlight 
(ultraviolet B). Cholecalciferol is converted in the liver to 
25-hydroxyvitamin D, which in turn is converted in the 
kidneys to vitamin D3, the biologically active form. Vitamin 
D3 crosses the blood – brain barrier and is locally synthesized 
in the brain from 25-hydroxyvitamin D. Cell-specifi c gene 
regulation occurs through interactions with the vitamin D 
receptor, a member of the steroid/thyroid hormone receptor 
superfamily. The receptor is widely distributed in the brain 
and other tissues. 
 Serum levels of 25-hydroxyvitamin D are lower in 
Alzheimer ’ s disease patients than healthy older adults 68 , and 
lower levels are associated with poorer cognitive function 
and increased Alzheimer risk 69 . An Institute of Medicine 
report, however, found insuffi cient support for vitamin D 
benefi t beyond recognized roles in calcium metabolism and 
bone health 70 . 
 One clinical trial met our search criteria 71 . This was 
a secondary analysis from the WHI trial of calcium and 
vitamin D (400 IU vitamin D3 daily) versus placebo. Many 
participants were simultaneously enrolled in the memory study 
component of the WHI MHT trial. Over a mean follow-up 
of more than 7 years, average scores on a screening cognitive 
test did not differ between treatment groups, nor did other 
neuropsychological test scores in a subgroup included in an 
ancillary analysis 71 . Our meta-analysis showed no cognitive 
effect of vitamin D. 
 Cognitive and physical activities 
 We did not undertake systematic reviews of cognitive activity 
and physical activity because these lifestyle interventions have 
been widely publicized, and recent meta-analyses provide a 
basis for interpretation and conclusions. 
 Cognitive activity and cognitive training 
 Use-dependent neural plasticity forms the basis of learning, 
memory, and skill acquisition. Engaging in cognitively stimu-
lating activity has the potential to ameliorate cognitive abili-
ties diminished by aging. The Advanced Cognitive Training 
for Independent and Vital Elderly (ACTIVE) trial provides 
partial support for the mantra,  ‘ use it or lose it ’ . This large-
scale randomized trial in community-dwelling older adults 
used interventions focused on memory, reasoning, or process-
ing speed 72 . Comparisons were to a no-intervention control. 
Training occurred in group sessions over a period of about 
5 weeks, and booster sessions were provided to a subset of 
participants. At 2 years, each active intervention improved 
cognitive skills within the targeted domain but not other 
cognitive domains 72 . Effects of the reasoning and processing 
speed interventions could still be detected 10 years later 73 . 
Training had no effect on everyday functioning at 2 years, 
but at 10 years self-reported functioning had declined less in 
cognitive training groups compared to the no-intervention 
group 72,73 . 
 A recent systematic review identifi ed 31 randomized trials 
of cognitive training or mental stimulation involving older 
adults without known existing cognitive impairment 74 . 
Compared to no intervention, cognitive training signifi cantly 
improved performance on several memory measures (face-
name recall, immediate recall, and paired associates learn-
ing, but not delayed recall). Compared to active controls, 
cognitive training improved performance on tasks involving 
memory (recognition) and other cognitive abilities (working 
memory, processing speed, and overall cognitive function-
ing). Similar fi ndings were reported in a preceding meta-
analysis 75 . 
 Aerobic physical activity 
 Aerobic exercise is thought to maintain brain health indi-
rectly through cardiovascular benefi t and directly through 
effects on cerebral fl ow, neurogenesis, increased production 
of brain-derived neurotrophic factor, and other mechanisms. 
A robust animal literature supports a role for aerobic activity 
in maintaining cognitive function and reducing brain 
pathology in animal models of Alzheimer ’ s disease. The 
observational literature extends these fi ndings to humans, 
showing inverse associations between regular physical 
exercise and cognitive decline, MCI, and Alzheimer ’ s 
disease 7,76,77 . Aerobic exercise (walking) compared to stretch-
ing exercise is reported to increase the size of the anterior 
hippocampus 78 . 
 A Cochrane Collaboration review assessed cognitive effects 
of aerobic exercise in 12 randomized trials 79 . Participants 
were aged 55 years and older. No intervention exceeded 
6 months. There were three 6-month trials, two with at 
least 50 participants 52,80 . The fi rst trial randomly assigned 
sedentary, healthy older adults to an aerobic (walking) or 
anaerobic (toning and stretching) intervention, with struc-
tured classes that met three times weekly 80 . Executive con-
trol processes improved in the walking group. The second 
was a three-armed trial that included walking (one class 
weekly plus home exercise) and a wait-list control 52 . Cog-
nitive function at trial completion did not differ between 
groups. In a 40-week trial not included in the Cochrane 
review, cognitive outcomes did not differ between partici-
pants in a thrice-weekly walking group and a no-intervention 
comparison group 54 . The Cochrane meta-analysis reported 
no evidence for cognitive benefi t when aerobic exercise was 
compared to an active intervention (eight trials including 
506 participants) or to no intervention at all (six trials, 
296 participants) 79 . Improved cardiorespiratory fi tness was 
not associated with cognitive improvement. The authors 
concluded that aerobic exercise, including activities that 
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improve cardiovascular fi tness, provides no cognitive benefi t 
in healthy older adults. 
 General discussion 
 A number of factors under an individual ’ s control might 
improve cognitive aging and  – although not a focus of this 
review  – at the same time reduce dementia risk through 
enhanced cognitive reserve and brain health. Unfortunately, 
evidence in many areas is still inadequate. This is true not only 
for medical and psychiatric disorders, most prescription medi-
cations, and early life exposures 7 but also for the individually 
modifi able factors considered in this review. Only four inter-
ventions in our meta-analysis included data from three or 
more clinical trials (B-vitamins, omega-3 polyunsaturated 
fatty acids, MHT, and soy isofl avones). Wide confi dence inter-
vals for some treatment effects (Figure 1) refl ect the small 
number of trials and relatively small sample sizes. 
 Most interventions considered in our meta-analysis did 
not show clinically meaningful effects on global cognition or 
memory, and none showed effects that could be characterized 
as large, or even medium. Cognitive effi cacy of the Mediterra-
nean diet was supported by just one trial, with data from two 
study sites. It is diffi cult to know which components of this 
multifaceted nutritional intervention contributed to observed 
benefi t. Because benefi t in this dietary trial was most apparent 
in the arm receiving olive oil supplements, fi ndings may not 
generalize to other versions of the Mediterranean diet. 
 Tai chi exercise also emerged as an intervention that may 
benefi t cognitive aging. We identifi ed only two eligible trials. 
We classifi ed tai chi as a mindfulness intervention, but this 
Eastern exercise also involves skill learning and aerobic activ-
ity of mild-to-moderate intensity, taught in a socially engag-
ing group setting. Benefi cial effects of soy isofl avone supple-
ments on memory (but not global cognition) and effects of 
cognitive training are other promising avenues for additional 
research. It should pointed out that isofl avone trials involved 
only women. High isofl avone dosages in these trials approxi-
mate levels of dietary consumption in several Asian countries 
but greatly exceed levels found in Western diets 81 . Our MHT 
results support guideline recommendations that MHT should 
not be used to ameliorate cognitive aging 82,83 . However, it 
is important to recognize that few clinical trials of MHT 
have included younger postmenopausal women and none has 
focused specifi cally on the largest group of women for whom 
MHT is indicated, namely women with moderate-to-severe 
vasomotor symptoms. 
 There are limitations to our fi ndings. We were unable to 
consider all individually modifi able risk factors, and our 
search strategy may not have identifi ed all eligible trials for 
factors that we did consider. An intervention might reduce 
dementia risk without necessarily improving cognitive aging. 
Exclusion of small trials to reduce publication bias could 
introduce other biases, and we did not formally evaluate trial 
quality. The focus on single interventions may underestimate 
effects of multimodal or combined approaches. Cognitive 
aging does not begin at midlife 84 , and effects of some individu-
ally modifi able interventions may be greater if implemented 
at an earlier age. 
 We conclude that individual choices can and do affect cog-
nitive aging. Benefi cial effects, when present, are likely to be 
modest but are nonetheless potentially important. However, 
we do not make specifi c recommendations in the absence 
of stronger evidence of meaningful effectiveness. Further 
research, particularly on dietary factors, cognitive activity, 
and multimodal leisure activities such as tai chi exercise seem 
especially warranted. 
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 Supplementary Table S1 Search terms used in PubMed searches 
 Search category  Search terms 
 Outcomes “memory”[MeSH Terms] OR “memory”[All Fields] OR “cognition”[MeSH Terms] OR 
“cognition”[All Fields] OR  “ cognitive ” [All Fields]
 Limitations  “ Randomized Controlled Trial ” [ptyp] AND “adult”[MeSH Terms]
 Interventions * 
B vitamins (Vitamin B12, folic acid, vitamin 
B6) (79 | 4)
“vitamin b 12”[MeSH Terms] OR “vitamin b 12”[All Fields] OR (“vitamin”[All Fields] 
AND “b12”[All Fields]) OR “vitamin b12”[All Fields] OR “cobalamin”[All Fields]) 
OR “vitamin b 6”[MeSH Terms] OR “vitamin b 6”[All Fields] OR  “ pyridoxine ” [All 
Fields] OR “folic acid”[MeSH Terms] OR “folate”[All Fields] OR “folic acid”[All 
Fields]
DHEA (38 | 1) (“dehydroepiandrosterone sulfate”[MeSH Terms] OR “dehydroepiandrosterone”[MeSH 
Terms] OR “dehydroepiandrosterone”[All Fields] OR “dehydroepiandrosterone 
sulfate”[All Fields] OR  “ prasterone ” [All Fields] OR  “ dhea * ” [All Fields]
Ginkgo biloba (108 | 0 † ) “ginkgo biloba”[MeSH Terms] OR (“ginkgo”[All Fields] AND “biloba”[All Fields]) OR 
“ginkgo biloba”[All Fields] OR (“ginkgo”[All Fields] AND “biloba”[All Fields]) OR 
“ginkgo biloba”[All Fields] OR “EGb 761”[All Fields]
Mediterranean diet (7 | 1 ‡ ) “diet, mediterranean”[MeSH Terms] OR (“diet”[All Fields] AND “mediterranean”[All 
Fields]) OR “mediterranean diet”[All Fields] OR (“mediterranean”[All Fields] AND 
“diet”[All Fields])
Menopausal hormone therapy (237 | 6 § ) “hormone replacement therapy”[MeSH Terms] OR “oestrogen”[All Fields] OR 
“estrogens”[Pharmacological Action] OR “estrogens”[MeSH Terms] OR 
“estrogens”[All Fields] OR “estrogen”[All Fields]
Mindfulness (306 | 3) “mindfulness”[MeSH Terms] OR “mindfulness”[All Fields]) OR “tai ji”[MeSH Terms] 
OR “tai ji”[All Fields] OR “tai chi”[All Fields] OR (“qigong”[MeSH Terms] OR 
“qigong”[All Fields] OR “qi gong”[All Fields] OR “meditation”[MeSH Terms] OR 
“meditation”[All Fields] OR “yoga”[MeSH Terms] OR “yoga”[All Fields] OR 
 “ mind-body ” [All Fields]
Omega-3 polyunsaturated fatty acids (56 | 3) “fatty acids, omega-3”[MeSH Terms] OR “omega-3”[All Fields] OR  “ alpha-linolenic 
acid”[MeSH Terms] OR  “ docosahexaenoic acids”[MeSH Terms] OR  “ eicosapentaenoic 
acid”[MeSH Terms] OR  “ linolenic”[All Fields] OR  “ docosahexaenoic”[All Fields] OR 
 “ eicosapentaenoic”[All Fields] OR “n 3 polyunsaturated fatty acid”[All Fields] OR “n 
3 polyunsaturated fatty acids”[All Fields]
Social engagement and social support (163 | 1) “social”[All Fields] AND (“engagement”[All Fields] OR “participation”[All Fields] OR 
“activity”[All Fields])
Soy isofl avones (22 | 4) soy[All Fields] OR “isofl avones”[MeSH Terms] OR “isofl avones”[All Fields] OR 
“isofl avone”[All Fields]) OR “soy foods”[MeSH Terms] OR (“soy”[All Fields] AND 
“foods”[All Fields]) OR “soy foods”[All Fields] OR “tofu”[All Fields]
Vitamin D (22 | 1) “vitamin d”[MeSH Terms] OR “vitamin d”[All Fields] OR “ergocalciferols”[MeSH 
Terms] OR “ergocalciferols”[All Fields] OR “cholecalciferol”[MeSH Terms] OR 
“cholecalciferol”[All Fields]
Cognitive training and cognitive activity Reviewed on basis of recent meta-analysis ‖ 
Physical activity (aerobic exercise) Reviewed on basis of recent meta-analysis ‖ 
 * Numbers in parentheses represent number of citations | number of eligible trials.  † Data from one otherwise eligible trial were not in a form 
that could be extracted for analysis (see text).  ‡ Three publications; one trial.  § Eight publications; six trials. An additional trial published after 
our systematic search is described in the text.  ‖ We did not undertake an independent systematic search on these topics (see text) 
 DHEA    dehydroepiandrosterone or dehydroepiandrosterone sulfate 
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 Supplementary Table S2 Cognitive effects of individually modifi able interventions: random-effects model 
 Global cognition  Episodic memory 
 Intervention 
 Standardized mean 
difference  95% CI 
 Standardized 
mean difference  95% CI 
B-vitamins 0.02   0.01 to 0.05 0.04 0.00 to 0.08
Dehydroepiandrosterone 0.06   0.10 to 0.22 0.12   0.15 to 0.39
Mediterranean diet   mixed nuts 0.08 0.03 to 0.14 0.07   0.03 to 0.17
Mediterranean diet   olive oil 0.22 0.16 to 0.27 0.22 0.12 to 0.32
Menopausal hormone therapy   0.03   0.05 to 0.00   0.01   0.04 to 0.03
Omega-3 fatty acids   0.02   0.04 to 0.01 0.02   0.04 to 0.07
Social engagement 0.12   0.02 to 0.25 0.20   0.08 to 0.47
Soy isofl avones 0.04 0.00 to 0.08 0.11 0.04 to 0.17
Tai chi exercise 0.18 0.06 to 0.29 0.24   0.03 to 0.51
Vitamin D 0.00   0.04 to 0.04   0.01   0.08 to 0.06
Yoga 0.02   0.12 to 0.17 0.06   0.38 to 0.50
 Standard mean differences and 95% confi dence intervals by intervention for primary (global cognition) and 
secondary (episodic memory) outcomes. Estimates from fi xed-effects and random-effects models are very 
similar 
 Supplementary Table S3 Effects of individually modifi able interventions: general intelligence (non-memory) 
outcomes 
 Fixed effects model  Random effects model 
 Intervention 
 Standardized 
mean difference  95% CI 
 Standardized 
mean difference  95% CI 
B-vitamins 0.01   0.03 to 0.04 0.00   0.04 to 0.04
Dehydroepiandrosterone 0.09   0.13 to 0.31 0.09   0.14 to 0.31
Mediterranean diet   mixed nuts 0.08 0.00 to 0.15 0.08 0.00 to 0.15
Mediterranean diet   olive oil 0.21 0.14 to 0.28 0.21 0.14 to 0.29
Menopausal hormone therapy   0.03   0.06 to 0.01   0.02   0.06 to 0.02
Omega-3 fatty acids   0.04   0.08 to -0.01   0.05   0.09 to 0.00
Social engagement 0.09   0.06 to 0.24 0.09   0.06 to 0.24
Soy isofl avones 0.01   0.05 to 0.06 0.01   0.05 to 0.06
Tai chi exercise 0.14 0.01 to 0.27 0.14 0.01 to 0.27
Vitamin D 0.00   0.06 to 0.06 0.00   0.07 to 0.07
Yoga 0.02   0.13 to 0.17 0.02   0.14 to 0.17
 Standard mean differences and 95% confi dence intervals by intervention for general intelligence outcomes. 
General intelligence was not a primary or secondary outcome, and results are not interpreted in the text 
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